tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Chemours sees FY25 revenue $5.9B-$6.0B, consensus $5.88B

Sees FY25 adjusted EBITDA $775M-$825M, with referenced Q3 operational disruptions in TT and outage impacts in APM totaling $35M, collectively, to be resolved in the Q4. Anticipated capital expenditures are expected to be approximately $250M, with Free Cash Flow Conversion to be between 60%-80% in the second half of 2025 through a seasonal net working capital unwind.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1